ParamjeetGKhoslaMDRFUMS

Oncology • Chicago, IL

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Chief of Hematology Oncology Professor of Medicine

Join to view full profile

Dr. Khosla is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Khosla's full profile

Already have an account?

Office
1501 S California Ave
Mt. Sinai Hospital Cancer center
Chicago, IL 60608
Phone+1 773-257-6120

Fax+1 773-257-6276

Summary

Dr. Paramjeet Khosla is an experienced Oncologist based in Chicago, IL. Her areas of specialty include Breast Cancer, Cancer Genetics/Cancer Risk Assessment and Hematologic Oncology. She completed her residency in Internal Medicine at Chicago Medical School/Rosalind Franklin University of Medicine & Science and her fellowship in Hematology and Medical Oncology at Tulane University. Dr. Khosla has a wealth of experience in conditions such as amyloidosis, hematologic oncology, breast cancer, myelodysplasia, and myelofibrosis. She has several published works and has participated in numerous clinical trials mainly focusing on cancer treatments. Notably, Dr. Khosla received a Clinical Trials Participation Award from ASCO in 2014.

Education & Training

Tulane UniversityFellowship, Hematology and Medical Oncology, 1995 - 1996
University of Illinois College of Medicine at ChicagoFellowship, Hematology and Medical Oncology, 1993 - 1995
Chicago Medical School/Rosalind Franklin University of Medicine & ScienceResidency, Internal Medicine, 1990 - 1993
Government Medical College PatialaClass of 1986

Certifications & Licensure

IL State Medical License 1990 - 2026
LA State Medical License 1995 - 1997
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Clinical Trials Participation Award ASCO, 2014

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Join now to see all

Publications & Presentations

PubMed

3 citations
Cardiovascular Adverse Events Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Therapy: A Systematic Review and Meta-analysis.
Ekaterina Proskuriakova, Dhan Bahadur Shrestha, Ranjit Jasaraj, Vijay Ketan Reddy, Jurgen Shtembari
Clinical Therapeutics. 2024-02-01
Are We the Problem? A Call to Action for Addressing Institutional Challenges to Engaging Community Partners in Research.
Neha Hippalgaonkar, Ryan Huu-Tuan Nguyen, Eliza Brumer Cohn, Joseph Horowitz, Ana Williams Waite
International Journal of Environmental Research and Public Health. 2024-02-17
Impact of Obesity on Breast Cancer Clinicopathological Characteristics in Underserved US Community Safety-Net Hospital: A Retrospective Single-Center Study.
Ekaterina Proskuriakova, Barun Babu Aryal, Dhan Bahadur Shrestha, Stephanie Valencia, Iuliia Kovalenko
Clinical Breast Cancer. 2024-08-13

Lectures

Multi-institution quality improvement in supportive oncology: Results of the Coleman Supportive Oncology Collaborative (CSOC).
2019 ASCO Annual Meeting - 6/1/2019